143 related articles for article (PubMed ID: 20149360)
1. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial.
Fatemi HM; Oberyé J; Popovic-Todorovic B; Witjes H; Mannaerts B; Devroey P
Fertil Steril; 2010 Oct; 94(5):1922-4. PubMed ID: 20149360
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
[TBL] [Abstract][Full Text] [Related]
3. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation.
Corifollitropin Alfa Dose-finding Study Group
Hum Reprod; 2008 Nov; 23(11):2484-92. PubMed ID: 18684735
[TBL] [Abstract][Full Text] [Related]
4. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.
Fauser BC; Mannaerts BM; Devroey P; Leader A; Boime I; Baird DT
Hum Reprod Update; 2009; 15(3):309-21. PubMed ID: 19182099
[TBL] [Abstract][Full Text] [Related]
5. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
6. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
[TBL] [Abstract][Full Text] [Related]
7. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
[TBL] [Abstract][Full Text] [Related]
8. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study.
Polyzos NP; Devos M; Humaidan P; Stoop D; Ortega-Hrepich C; Devroey P; Tournaye H
Fertil Steril; 2013 Feb; 99(2):422-6. PubMed ID: 23084565
[TBL] [Abstract][Full Text] [Related]
9. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
[TBL] [Abstract][Full Text] [Related]
10. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.
Blockeel C; Polyzos NP; Derksen L; De Brucker M; Vloeberghs V; van de Vijver A; De Vos M; Tournaye H
Hum Reprod; 2014 Jul; 29(7):1500-7. PubMed ID: 24813196
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.
Hwang JL; Chen SU; Chen HJ; Chen HF; Yang YS; Chang CH; Seow KM; Tzeng CR; Lin YH
J Formos Med Assoc; 2018 Jun; 117(6):535-540. PubMed ID: 28830648
[TBL] [Abstract][Full Text] [Related]
12. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study.
Papanikolaou EG; Verpoest W; Fatemi H; Tarlatzis B; Devroey P; Tournaye H
Fertil Steril; 2011 Mar; 95(3):1174-7. PubMed ID: 20979997
[TBL] [Abstract][Full Text] [Related]
13. A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.
Wang HL; Lai HH; Chuang TH; Shih YW; Huang SC; Lee MJ; Chen SU
PLoS One; 2016; 11(4):e0154123. PubMed ID: 27100388
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa.
Griesinger G; Teal V; McCrary Sisk C; Ruman J
Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():101-105. PubMed ID: 30529793
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
Oehninger S; Nelson SM; Verweij P; Stegmann BJ
Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
[TBL] [Abstract][Full Text] [Related]
16. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem.
Huber M; Hadziosmanovic N; Berglund L; Holte J
Fertil Steril; 2013 Nov; 100(5):1270-6. PubMed ID: 23931964
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
Devroey P; Boostanfar R; Koper NP; Mannaerts BM; Ijzerman-Boon PC; Fauser BC;
Hum Reprod; 2009 Dec; 24(12):3063-72. PubMed ID: 19684043
[TBL] [Abstract][Full Text] [Related]
18. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
[TBL] [Abstract][Full Text] [Related]
19. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone.
Kolibianakis EM; Papanikolaou EG; Tournaye H; Camus M; Van Steirteghem AC; Devroey P
Fertil Steril; 2007 Nov; 88(5):1382-8. PubMed ID: 17445806
[TBL] [Abstract][Full Text] [Related]
20. Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation.
de Greef R; Zandvliet AS; de Haan AF; Ijzerman-Boon PC; Marintcheva-Petrova M; Mannaerts BM
Clin Pharmacol Ther; 2010 Jul; 88(1):79-87. PubMed ID: 20520605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
